In contrast, in the Impassion 131 trial, paclitaxel plus atezolizumab did not produce a significant difference in PFS among PD-L1-positive or intention-to-treat groups of patients with advanced triple-negative breast cancer who had completed adjuvant chemotherapy or had not received any therapy [217]. Here, CD274 is linked to triple-negative breast carcinoma.